ASTERDM:NSE-Aster DM Healthcare Limited (INR)

COMMON STOCK | Medical Care Facilities | NSE

Last Closing Price

INR 216.35

Change

-10.90 (-4.80)%

Market Cap

INR 108.07B

Volume

0.01B

Avg Analyst Target

INR 200.00 (-7.56%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aster DM Healthcare Limited operates as a healthcare company in India and internationally. It provides primary, secondary, tertiary, and quaternary healthcare services through 27 hospitals, 115 clinics, and 223 retail pharmacies under the Aster, Medcare, and Access brands. The company was founded in 1987 and is headquartered in Dubai, the United Arab Emirates. Address: Tower D - Aspect Tower, Dubai, United Arab Emirates

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-17 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APOLLOHOSP:NSE Apollo Hospitals Enterprise Li..

+27.50 (+0.56%)

INR705.73B 81.73 36.16
MAXHEALTH:NSE Max Healthcare Institute Limit..

-18.40 (-4.63%)

INR374.30B 108.67 49.85
FORTIS:NSE Fortis Healthcare Limited

-5.35 (-1.96%)

INR202.29B 60.80 18.49
NH:NSE Narayana Hrudayalaya Limited

-6.15 (-1.14%)

INR108.88B 59.58 27.32
HCG:NSE HealthCare Global Enterprises ..

+12.60 (+5.23%)

INR31.79B N/A 44.11
SHALBY:NSE Shalby Limited

-5.20 (-2.75%)

INR19.88B 27.95 15.03
MAXINDIA:NSE Max Healthcare Institute Limit..

N/A

INR18.42B 5.20 N/A
INDRAMEDCO:NSE Indraprastha Medical Corporati..

-1.20 (-1.50%)

INR7.22B 17.09 7.32
LOTUSEYE:NSE Lotus Eye Hospital and Institu..

-1.05 (-2.19%)

INR0.98B 48.55 20.39

ETFs Containing ASTERDM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.32% 25% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.32% 25% F 41% F
Trailing 12 Months  
Capital Gain 48.54% 13% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.54% 13% F 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.52% 13% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.52% 13% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 22.59% 100% A+ 92% A-
Risk Adjusted Return 2.31% 13% F 31% F
Market Capitalization 108.07B 56% F 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.19 75% C 27% F
Price/Book Ratio 3.42 56% F 33% F
Price / Cash Flow Ratio 6.89 100% A+ 55% F
EV/EBITDA 12.78 89% B+ 50% F
Management Effectiveness  
Return on Equity 4.71% 78% C+ 40% F
Return on Invested Capital 12.00% 100% A+ 75% C
Return on Assets 2.32% 67% D+ 46% F
Debt to Equity Ratio 52.03% 25% F 25% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.03 25% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.